MPA vs GnRH antagonist for LH surge prevention in ART shows higher oocyte yield in fertility preservation cycles
Could a common pill help women freeze more eggs for the future?
A retrospective observational cohort study of 2,964 ART cycles at a Chilean fertility clinic compared oral medroxyprogesterone acetate (MPA)…
A common oral pill helped women freeze more mature eggs for the future than standard daily injections in a review of nearly 3,000 fertility …
Letrozole reduces Ki67 in postmenopausal ER+/HER2- breast cancer after 7-30 days pre-surgery
Can a short course of letrozole before surgery help shrink hormone-sensitive breast cancer?
A phase 2 trial of 61 postmenopausal women with ER+/HER2- operable breast cancer evaluated a 7- to 30-day preoperative course of letrozole 2…
Doctors can now get a real-time snapshot of how hormone-sensitive breast cancer responds to letrozole before surgery in postmenopausal women…
Sentinel lymph node technique assessed in multifocal breast cancer (n=216)
Can doctors find the first lymph node cancer might reach in women with multiple breast tumors?
A phase 2 trial assessed the sentinel lymph node technique in 216 patients with multifocal breast cancer.
Doctors successfully mapped the first lymph node cancer reaches in women with multiple breast tumors using a safe dye and tracer injection t…
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN
Can a gentler, three-part treatment plan reduce side effects for head and neck cancer?
A single-arm phase II trial enrolled 40 previously untreated patients with SCCHN amenable to transoral surgery.
A three-part treatment plan for head and neck cancer aims to reduce harsh side effects by tailoring care based on surgery results.
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…
Triapine Added to Cisplatin and Radiation for Cervical/Vaginal Cancer: Phase III Results
Could a new drug boost survival for women with advanced cervical and vaginal cancers?
Phase III trial evaluates triapine with cisplatin and radiation vs. standard treatment for advanced cervical and vaginal cancers.
A new drug called triapine may help women with advanced cervical and vaginal cancers live longer when added to standard radiation and chemot…
Study Validates Genotype Predictor of TIPN in African American Breast Cancer Patients
Could your genes predict nerve pain from breast cancer treatment?
This phase II trial with 249 participants evaluates a germline predictor of taxane-induced peripheral neuropathy (TIPN) in African American …
A genetic marker may predict severe nerve pain from breast cancer chemo in African American patients, with docetaxel possibly causing fewer …
Phase 1/2 Study of Dual-Target CAR-NK Cells in Recurrent Ovarian Cancer
Could New Cell Therapy Change the Game for Women with Recurrent Ovarian Cancer?
This Phase 1/2 trial assesses the safety and preliminary efficacy of dual-target CAR-NK cells in recurrent ovarian cancer, focusing on dose-…
Women with recurrent ovarian cancer may find new hope in a trial testing dual-target CAR-NK cells designed to attack tumors that resist stan…
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
Could a Simple Test Help Tailor Breast Cancer Treatment?
Phase II study shows RAD51-foci score predicts olaparib response in BRCA1/2, PALB2, RAD51C/D mutated breast cancer. Study enrolled 65 patien…
A new test may help doctors choose the right drug sooner for women with advanced breast cancer who have specific genetic mutations.
Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes
Can a Common Breast Cancer Drug Work Better for Some Patients?
This Phase 2/3 trial examines the relationship between ER and UGT SNPs and Raloxifene's efficacy and side effects in 600 BC-LCIS patients. R…
A study is testing if genetic markers can predict which breast cancer patients respond best to Raloxifene, potentially tailoring treatment f…